实用医学杂志 ›› 2026, Vol. 42 ›› Issue (11): 1996-2006.doi: 10.3969/j.issn.1006-5725.2026.11.014
• 慢性病防治专栏 • 上一篇
收稿日期:2026-01-23
出版日期:2026-06-10
发布日期:2026-06-15
通讯作者:
孙新宇
E-mail:sunxinyu634@126.com
基金资助:Received:2026-01-23
Online:2026-06-10
Published:2026-06-15
Contact:
Xinyu SUN
E-mail:sunxinyu634@126.com
摘要:
糖尿病肾病(diabetic kidney disease, DKD)是糖尿病(diabetes mellitus, DM)最常见且最严重的微血管并发症之一,是慢性肾脏病(chronic kidney disease,CKD)和终末期肾病(end-stage renal disease,ESRD)的主要原因,给患者和社会带来沉重的健康与经济负担。肠道菌群是寄居在人体肠道内的所有微生物的总和,是一个极其复杂且庞大的生态系统。肠道菌群和肾脏间的有机相互作用已被证明直接或间接地影响人体健康,其中肠道菌群失调、肠道屏障受损、肠道菌群代谢产物失衡会引发氧化应激、免疫炎症反应,加速DKD的进展。中医药以其多靶点、整体调节、副作用小的特点在防治DKD方面展现出独特的优势。研究发现,中药单体苷类、黄酮类、多酚类、萜类、生物碱类、多糖类等多种化合物及祛瘀泄浊、益气养阴、清热解毒等类别的中药复方通过调节肠道菌群,靶向相关信号通路,减轻肾损伤,延缓DKD进展。该文系统梳理了肠道菌群参与DKD的关键机制,分析了近年来中药单体及复方在DKD治疗中调节肠道菌群方面所取得的研究成果,以期为中医药防治DKD提供新的思路和方向。
中图分类号:
周秋雨,孙新宇. 基于肠道菌群探讨中医药治疗糖尿病肾病的研究进展[J]. 实用医学杂志, 2026, 42(11): 1996-2006.
Qiuyu ZHOU,Xinyu SUN. Research progress on the treatment of diabetic kidney disease with traditional chinese medicine based on gut microbiota[J]. The Journal of Practical Medicine, 2026, 42(11): 1996-2006.
表1
中药单体调节肠道菌群治疗DKD总结"
| 类别 | 成分名称 | 肠道菌群变化 | 作用机制 | 参考文献 |
|---|---|---|---|---|
| 苷类 | 人参皂苷化合物K | 拟杆菌属↓;副普雷沃菌属↓; 乳酸菌属↑;阿克曼菌属↑ | IMP激活TLR4信号通路↓ | [ |
| 黄芪甲苷Ⅳ | 阿克曼菌属↑;Ligilactobacillus↑; 乳杆菌属↑ | 炎症、铁死亡↓ | [ | |
| 黄精皂苷 | 拟杆菌门↑;厚壁菌门↓ | HDL-C↑;INS、FBG、TG、TC、LDL-C↓ | [ | |
| 肉苁蓉苯乙醇苷 | 调节coprostanoligenes_group、 Oscillospiraceae_UCG-005等的丰度 | 维生素B6、酪氨酰色氨酸↑ 组胺、L-蛋氨酸↓ | [ | |
| 黄酮类 | 仙人掌类黄酮 | 拟杆菌属↑;阿克曼菌属↑; 另枝菌属↓;脱硫弧菌科↓ 螺杆菌属↓ | SCFA↑ | [ |
| 王不留行黄酮苷 | B/F↑;拟杆菌属↑;乳杆菌属↑; 另枝菌属↑;瘤胃球菌属↓ | TBA↓ FXR和TGR5受体的表达↑ | [ | |
| 异荭草素 | 革兰阴性细菌(如颤杆菌属)↓ | LPS↓ | [ | |
| 槲皮素 | 布劳特菌属↓ | 苯丙氨酸代谢↓;肾毒性代谢物↓;肾损伤标志物↓;促炎细胞因子↓ | [ | |
| 多酚类 | 白藜芦醇 | 粪杆菌↑;乳酸杆菌↑ | SCFA(尤其是C2)↑ | [ |
| 安石榴苷 | 重塑肠道微生物生态 | SCFA↑;LPS、DAO↓ | [ | |
| 姜黄素 | Lachnospiraceae_NK4A136_group↑ Eubacterium_siraeum_group↑ Muribaculaceae↑ | SCFA↑ 尿毒症潴留溶质↓ LPS/TLR4/NF-κB及TGF-β1/Smads通路↓ | [ | |
| 石斛多酚 | B/F↑ 普雷沃菌/阿克曼菌菌↑ S24-7/Rikenella/大肠杆菌↓ | SOD、CAT、GSH↑ MDA、IL-6、TNF-α↓ | [ | |
| 萜类 | 茯苓酸A | 乳酸菌↑ 阿克曼菌↑ | 肠道紧密连接蛋白的表达↑;SCFA↑;内毒素介导的全身炎症↓ 尿蛋白↓;AMPK表达↑ | [ |
| 积雪草酸 | 变形菌门↑;约翰逊乳杆菌↑; 厚壁菌门↓ | Occludin、Claudin、Zo-1的mRNA表达及Occludin、Claudin的蛋白水平↑ | [ | |
| 生物碱类 | 桑枝生物碱 | 杜波菌属↑;乳杆菌属↑ | 十五烷酸↑ | [ |
| 小檗碱 | 粪杆菌↑;玫瑰花杆菌↑ | C4↑;促炎细胞因子↓;Nfkb1、Stat1和Ifnrg1的表达↓ | [ | |
| 乌头生物碱 | 埃希菌-志贺菌↓;梭状芽孢杆菌↓ 瘤胃球菌↓;Ligilactobacillus↑ Anaerotruncus↑;拟杆菌属↑ 脱硫弧菌属↑ | 尿毒症毒素↓;SCFA↑;NF-κB通路相关蛋白的表达↓ Nrf2/HO-1通路相关蛋白的表达↑;IL-1β、IL-6、TNF-α↓ SOD、CAT、GSH↑ | [ | |
| 多糖类 | 黄芪多糖 | 鼠杆菌科↑ 瘤胃球菌属_1↑ 考拉杆菌属↑ 毛螺菌属↑ | FBG、BUN、Cr、UA、MDA、TC、TG水平↓ GSH、GSH-PX、SOD活性↑ Nrf2、GCLC、NQO1、HO-1的mRNA和蛋白表达↑ TLR4、NLRP3、p-NF-κB、TGF-β、Smad4的蛋白表达↓ | [ |
| 玉米须多糖 | 毛螺菌科NK4A136_group↑ 杜波菌↑ | 调节内源性物质(如BA和尿毒症毒素)的异常代谢 | [ | |
| 冬虫夏草多糖 | 益生菌↑ | TLR4/NF-κB、TGF-β1/Smad信号通路↓ LPS诱导的炎性细胞因子水平↓ TGF-β1诱导的成纤维细胞活化↓ | [ | |
| 牛蒡多糖 | 脱硫弧菌属↓ 鼠杆菌属↑ | 肠道紧密连接蛋白和肠道黏蛋白的表达↑ 肠毒素和炎症介质的泄漏↓ | [ | |
| 牡丹皮多糖 | 乳酸杆菌↑ Muribaculaceae_unclassified↑ | 改善肠道屏障功能,减少血清促炎介质,并提高SCFA含量 | [ | |
| 其他类 | Daphnetin (香豆素衍生物) | 厚壁菌门↓ 拟杆菌门↑ | KIM-1、BUN、尿素、Scr、uNGAL、UA、炎性细胞因子和炎性介质、MDA、蛋白羰基↓;GR、SOD、GSH、CAT↑ | [ |
| 水蛭素 | 恢复肠道菌群体内平衡 | Claudin-1和Occludin表达↑;NLRP3-ASC-caspase-1通路↓ | [ | |
| 大黄素 | 梭状芽孢杆菌属↓;乳酸菌属↑ | 尿毒症毒素尿素和IS水平↓ | [ |
表2
中药复方调节肠道菌群治疗DKD总结"
| 类别 | 复方名称 | 作用机制 | 主要结果 | 参考文献 |
|---|---|---|---|---|
| 祛瘀泄浊类 | 复方贞术调脂方 | 魏斯菌属↓;肠球菌属↓; 阿克曼菌属↓ | 紧密连接蛋白的表达↑ SCFA(C3和C4)↑ SCFA转运蛋白Slc22a19水平↑ | [ |
| 升清降浊胶囊 | 植物乳杆菌↑;格氏乳杆菌↓; 罗伊杆菌↓ | 棕榈酰乙醇酰胺、油酸酰胺↑ FBG、UACR↓ | [ | |
| 糖肾方 | 变形菌门的肠杆菌科↓ 厚壁菌门的瘤胃球菌属↓ 放线菌门的双歧杆菌属↑ | IS、LPS↓ 芳基烃和TLR4的表达↓ JNK和NF-κB信号传导↓ | [ | |
| 益气养阴类 | 肾炎康复片 | 厚壁菌门↑;拟杆菌门↓ | NF-κB通路↓;TNF-α、IL-1β水平↓ | [ |
| 滋膵饮 | 普雷沃菌科↑;乳杆菌科↑; 肠杆菌↓;梭状芽孢杆菌科↓; 微球菌科↓; | 改善肾小球滤过率(eGFR)及SCr、尿白蛋白排泄率、24h UP、 UACR、HbA1c水平 | [ | |
| 参芪地黄汤 | 拟杆菌↑;双歧杆菌↑; 乳酸杆菌↑;肠杆菌↓; 肠球菌↓;酵母菌↓ | eGFR↑ 24h UP、UACR、MAU、尿β2-MG、SCr、KIM-1、CysC、HbA1c、 IL-1β、IL-6、TNF-α、TGF-β1水平↓ | [ | |
| 清热解毒类 | 黄葵胶囊 | 类粪杆状菌属↑;鼠杆菌属↑; 叶杆菌属↓;魏斯菌属↓; 阿克曼菌↓ | 调节蛋氨酸亚砜、BCAAs和顺-7-十六碳烯酸等氨基酸和脂肪酸类血浆代谢物水平恢复正常 | [ |
| 清热消癥方 | 理研菌科↑;阿克曼菌↑ | SCFA↑;LPS↓;LPS/TLR4/NF-κB炎症信号通路↓ ZO-1表达↑;血清FITC-葡聚糖水平↓ | [ | |
| 降糖汤 | 理研菌属↑;毛螺菌属↑; unclassified_c_Bacilli属↑; norank_f_Lachnospiraceae属↓ | 体质量、血糖、BUN、Cr、KIM-1、TMAO、PCS、IS、NLRP3、 IL-17A、IL-6以及尿蛋白水平↓ | [ | |
| 补虚固肾类 | 芪地糖肾颗粒 | 乳酸菌↓;拟杆菌属↓; 毛螺菌NK4A136_group↓; 拟普雷沃菌属↑; | TBA和BA谱水平↓ | [ |
| 复方仙草颗粒 | 拟普雷沃菌属↑;颤杆菌科↑; 厌氧支原体属↑;厌氧截形菌属↑; 粪杆菌属↓;F/B↓; | 参与碳水化合物和氨基酸的代谢,调控PI3K/Akt和MAPK炎症相关通路,改善DKD大鼠葡萄糖代谢紊乱和肾功能,减轻炎症,延缓肾脏病理改变 | [ | |
| 缩泉益肾方 | 蓝藻菌门↑;疣微菌门↑; 软壁菌门↓;放线菌门↓; F/B↓ | 血糖、BUN及UCr↓ | [ |
| [1] |
SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. doi: 10.1016/J.diabres.2021.109119 .
doi: 10.1016/J.diabres.2021.109119 |
| [2] |
THOMAS M C, BROWNLEE M, SUSZTAK K, et al. Diabetic kidney disease[J]. Nat Rev Dis Primers, 2015, 1: 15018. doi: 10.1038/NRDP.2015.18 .
doi: 10.1038/NRDP.2015.18 |
| [3] |
LIU W, WANG L, OU J, et al. Gut Microbiota Metabolites and Chronic Diseases: Interactions, Mechanisms, and Therapeutic Strategies[J]. Int J Mol Sci, 2025, 26(8): 3752. doi: 10.3390/IJMS26083752 .
doi: 10.3390/IJMS26083752 |
| [4] |
GIORDANO L, MIHAILA S M, ESLAMI AMIRABADI H, et al. Microphysiological Systems to Recapitulate the Gut-Kidney Axis[J]. Trends Biotechnol, 2021, 39(8): 811-823. doi: 10.1016/j.tibtech.2020.12.001 .
doi: 10.1016/j.tibtech.2020.12.001 |
| [5] |
WU X, ZHAO L, ZHANG Y, et al. The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease[J]. Front Physiol, 2023, 14: 1166685. doi: 10.3389/fphys.2023.1166685 .
doi: 10.3389/fphys.2023.1166685 |
| [6] |
ZAKY A, GLASTRAS S J, WONG M Y W, et al. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease[J]. Int J Mol Sci, 2021, 22(17): 9614. doi: 10.3390/IJMS22179641 .
doi: 10.3390/IJMS22179641 |
| [7] |
TIAN E, WANG F, ZHAO L, et al. The pathogenic role of intestinal flora metabolites in diabetic nephropathy[J]. Front Physiol, 2023, 14: 1231621. doi: 10.3389/fphys.2023.1231621 .
doi: 10.3389/fphys.2023.1231621 |
| [8] |
LIN J, WANG Z, SUN J, et al. Gut microbiota and diabetic kidney diseases: Pathogenesis and therapeutic perspectives[J]. World J Diabetes, 2022, 13(4): 308-318. doi: 10.4239/WJD.V13.i4.308 .
doi: 10.4239/WJD.V13.i4.308 |
| [9] |
ZHANG Y, QING J, SAED Y A, et al. Gut microbiota implication in diabetic kidney disease: Mechanisms and novel therapeutic strategies[J]. Ren Fail, 2025, 47(1): 2517402. doi: 10.1080/0886022X.2025.2517402 .
doi: 10.1080/0886022X.2025.2517402 |
| [10] |
SUZUKI T. Regulation of the intestinal barrier by nutrients: The role of tight junctions[J]. Anim Sci J, 2020, 91(1): e13357. doi: 10.1111/ASJ.13357 .
doi: 10.1111/ASJ.13357 |
| [11] |
WANG P, WANG T, ZHENG X, et al. Gut microbiota, key to unlocking the door of diabetic kidney disease[J]. Nephrology (Carlton), 2021, 26(8): 641-649. doi: 10.1111/nep.13874 .
doi: 10.1111/nep.13874 |
| [12] |
TAO P, JI J, WANG Q, et al. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease[J]. Front Immunol, 2022, 13: 1080456. doi: 10.3389/fimmu.2022.1080456 .
doi: 10.3389/fimmu.2022.1080456 |
| [13] |
AN J, LIU Y, WANG Y, et al. The Role of Intestinal Mucosal Barrier in Autoimmune Disease: A Potential Target[J]. Front Immunol, 2022, 13: 871713. doi: 10.3389/fimmu.2022.871713 .
doi: 10.3389/fimmu.2022.871713 |
| [14] |
LINH H T, IWATA Y, SENDA Y, et al. Intestinal Bacterial Translocation Contributes to Diabetic Kidney Disease[J]. J Am Soc Nephrol, 2022, 33(6): 1105-1119. doi: 10.1681/ASN. 2021060843 .
doi: 10.1681/ASN. 2021060843 |
| [15] |
FARRE R, DEJONGH S, MEIJERS B. Of Mice and MAVS-Diabetic Kidney Disease and the Leaky Gut[J]. J Am Soc Nephrol, 2022, 33(6): 1053-1055. doi: 10.1681/ASN. 2022040407 .
doi: 10.1681/ASN. 2022040407 |
| [16] |
SNELSON M, DE PASQUALE C, EKINCI E I, et al. Gut microbiome, prebiotics, intestinal permeability and diabetes complications[J]. Best Pract Res Clin Endocrinol Metab, 2021, 35(3): 101507. doi: 10.1016/J.Beem.2021.101507 .
doi: 10.1016/J.Beem.2021.101507 |
| [17] |
陈慧, 鲁一兵. 肠道菌群与糖尿病性肾小球硬化的研究进展[J]. 实用医学杂志, 2021, 37(3): 415-418. doi: 10.3969/j.issn.1006-5725.2021.03.028 .
doi: 10.3969/j.issn.1006-5725.2021.03.028 |
| [18] |
GONZALEZ A, KRIEG R, MASSEY H D, et al. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression[J]. Nephrol Dial Transplant, 2019, 34(5): 783-794. doi: 10.1093/ndt/gfy238 .
doi: 10.1093/ndt/gfy238 |
| [19] |
CAI K, MA Y, CAI F, et al. Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury[J]. Endocrine, 2022, 76(2): 294-303. doi: 10.1007/S12020-022-03002-1 .
doi: 10.1007/S12020-022-03002-1 |
| [20] |
LU J, CHEN P P, ZHANG J X, et al. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway[J]. Int J Biol Sci, 2022, 18(1): 96-111. doi: 10.7150/ijbs.64665 .
doi: 10.7150/ijbs.64665 |
| [21] |
LUO L, LUO J, CAI Y, et al. Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy[J]. Pharmacol Res, 2022, 183: 106367. doi: 10.1016/j.phrs. 2022.106367 .
doi: 10.1016/j.phrs. 2022.106367 |
| [22] |
AHMED S, SPARIDANS R W, VERNOOIJ R W M, et al. Protein-bound uremic toxin clearance as biomarker of kidney tubular function in diabetic kidney disease[J]. Sci Rep, 2025, 15(1): 23406. doi: 10.1038/s41598-025-07248-3 .
doi: 10.1038/s41598-025-07248-3 |
| [23] |
LIU W, TOMINO Y, LU K. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120[J]. Toxins (Basel), 2018, 10(9): 367. doi: 10.3390/toxins10090367 .
doi: 10.3390/toxins10090367 |
| [24] |
FANG Q, ZHENG B, LIU N, et al. Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease[J]. Front Physiol, 2021, 12: 682482. doi: 10.3389/fphys.2021.682482 .
doi: 10.3389/fphys.2021.682482 |
| [25] |
ANDRIKOPOULOS P, ARON-WISNEWSKY J, CHAKAROUN R, et al. Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide[J]. Nat Commun, 2023, 14(1): 5843. doi: 10.1038/s41467-023-39824-4 .
doi: 10.1038/s41467-023-39824-4 |
| [26] |
XIAO X, ZHANG J, JI S, et al. Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease[J]. Front Endocrinol (Lausanne), 2022, 13: 1026995. doi: 10.3389/fendo.2022.1026995 .
doi: 10.3389/fendo.2022.1026995 |
| [27] |
LIU P, JIN M, HU P, et al. Gut microbiota and bile acids: Metabolic interactions and impacts on diabetic kidney disease[J]. Curr Res Microb Sci, 2024, 7: 100315. doi: 10.1016/J.Crmicr. 2024.100315 .
doi: 10.1016/J.Crmicr. 2024.100315 |
| [28] |
WANG X X, WANG D, LUO Y, et al. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity[J]. J Am Soc Nephrol, 2018, 29(1): 118-137. doi: 10.1681/ASN.2017020222 .
doi: 10.1681/ASN.2017020222 |
| [29] |
YANG Z, XIONG F, WANG Y, et al. TGR5 activation suppressed S1P/S1P2 signaling and resisted high glucose-induced fibrosis in glomerular mesangial cells[J]. Pharmacol Res, 2016, 111: 226-236. doi: 10.1016/j.phrs.2016.05.035 .
doi: 10.1016/j.phrs.2016.05.035 |
| [30] |
MARQUARDT A, AL-DABET M M, GHOSH S, et al. Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy[J]. J Am Soc Nephrol, 2017, 28(11): 3182-3189. doi: 10.1681/ASN. 2016101123 .
doi: 10.1681/ASN. 2016101123 |
| [31] |
梁磊, 念馨. 肠道菌群:未来2型糖尿病治疗的新靶点[J]. 实用医学杂志, 2022, 38(3): 261-265. doi: 10.3969/j.issn.1006-5725.2022.03.001 .
doi: 10.3969/j.issn.1006-5725.2022.03.001 |
| [32] |
WANG M, GONG Q, ZHA C, et al. Low-dose lipopolysaccharide inducing continuous and obvious increase in urinary protein in hyperglycemic rats and the underlying mechanism[J]. PLoS One, 2023, 18(7): e288876. doi: 10.1371/journal.pone. 0288876 .
doi: 10.1371/journal.pone. 0288876 |
| [33] |
LINDFORS S, POLIANSKYTE-PRAUSE Z, BOUSLAMA R, et al. Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo[J]. Diabetologia, 2021, 64(8): 1866-1879. doi: 10.1007/s00125-021-05473-9 .
doi: 10.1007/s00125-021-05473-9 |
| [34] |
NI Y, DU H, KE L, et al. Gut-kidney interaction reinforces dapagliflozin-mediated alleviation in diabetic nephropathy[J]. Am J Physiol Cell Physiol, 2025, 328(2): C452-C466. doi: 10.1152/ajpcell.00651.2024 .
doi: 10.1152/ajpcell.00651.2024 |
| [35] |
CHEN Q, REN D, LIU L, et al. Ginsenoside Compound K Ameliorates Development of Diabetic Kidney Disease through Inhibiting TLR4 Activation Induced by Microbially Produced Imidazole Propionate[J]. Int J Mol Sci, 2022, 23(21): 12863. doi: 10.3390/ijms232112863 .
doi: 10.3390/ijms232112863 |
| [36] |
LYU X, ZHANG T, YE Z, et al. Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis[J]. Mol Nutr Food Res, 2024, 68(6): e2300734. doi: 10.1002/mnfr.202300734 .
doi: 10.1002/mnfr.202300734 |
| [37] |
CHAI Y, LUO J, BAO Y. Effects of Polygonatum sibiricum saponin on hyperglycemia, gut microbiota composition and metabolic profiles in type 2 diabetes mice[J]. Biomed Pharmacother, 2021, 143: 112155. doi: 10.1016/j.biopha.2021.112155 .
doi: 10.1016/j.biopha.2021.112155 |
| [38] |
MA C, JU B, LIU J, et al. Phenylethanol Glycosides from Cistanche tubulosa Modulate the Gut Microbiota and Cecal Metabolites to Ameliorate Diabetic Nephropathy Induced by Streptozotocin Combined with High-Fat Diet in Rats[J]. J Med Food, 2025, 28(3): 219-231. doi: 10.1089/jmf.2024.k.0175 .
doi: 10.1089/jmf.2024.k.0175 |
| [39] |
LIAO H, ZHAO Y, LIANG Y, et al. Flavonoids Derived from Opuntia ficus-indica Fruit Alleviate Renal Injury in Diabetic Nephropathy Mice by Altering Gut Microbiota and Promoting the Production of SCFAs[J]. Nutrients, 2025, 17(11): 1800. doi: 10.3390/nu17111800 .
doi: 10.3390/nu17111800 |
| [40] |
于晓依, 常畅, 陈天笑, 等. 王不留行黄酮苷改善糖尿病肾病小鼠肠道菌群紊乱和肾脏脂质沉积的研究[J]. 华西药学杂志, 2024, 39(1): 36-42. doi: 10.13375/j.cnki.wcjps.2024. 01.008 .
doi: 10.13375/j.cnki.wcjps.2024. 01.008 |
| [41] |
YUAN L, LI X, HE S, et al. Effects of Natural Flavonoid Isoorientin on Growth Performance and Gut Microbiota of Mice[J]. J Agric Food Chem, 2018, 66(37): 9777-9784. doi: 10.1021/acs.jafc.8b03568 .
doi: 10.1021/acs.jafc.8b03568 |
| [42] |
PENG B, DAI J, JI S, et al. Quercetin ameliorates hyperuricemic nephropathy through improving gut dysfunctions and decreasing gut bacteria-derived uremic toxins[J]. Phytomedicine, 2025, 143: 156801. doi: 10.1016/j.phymed.2025.156801 .
doi: 10.1016/j.phymed.2025.156801 |
| [43] |
YAN H, ZHANG Y, LIN X, et al. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in db/db mice[J]. Int J Food Sci Nutr, 2024, 75(3): 264-276. doi: 10.1080/09637486.2024.2303041 .
doi: 10.1080/09637486.2024.2303041 |
| [44] |
HUA Q, HAN Y, ZHAO H, et al. Punicalagin alleviates renal injury via the gut-kidney axis in high-fat diet-induced diabetic mice[J]. Food Funct, 2022, 13(2): 867-879. doi: 10.1039/d1fo03343c .
doi: 10.1039/d1fo03343c |
| [45] |
LI C, CHEN X, YAO J, et al. Curcumin modulated gut microbiota and alleviated renal fibrosis in 5/6 nephrectomy-induced chronic kidney disease rats[J]. PLoS One, 2025, 20(1): e314029. doi: 10.1371/journal.pone.0314029 .
doi: 10.1371/journal.pone.0314029 |
| [46] |
LI X, CHEN H, HE Y, et al. Effects of Rich-Polyphenols Extract of Dendrobium loddigesii on Anti-Diabetic, Anti-Inflammatory, Anti-Oxidant, and Gut Microbiota Modulation in db/db Mice[J]. Molecules, 2018, 23(12): 3245. doi: 10.3390/molecules23123245 .
doi: 10.3390/molecules23123245 |
| [47] |
WANG X, XU Y, WANG Y, et al. Poricoic Acid A Protects Against High-Salt-Diet Induced Renal Fibrosis by Modulating Gut Microbiota and SCFA Metabolism[J]. Plant Foods Hum Nutr, 2025, 80(2): 115.doi: 10.1007/s11130-025-01356-1 .
doi: 10.1007/s11130-025-01356-1 |
| [48] |
NI Y, PAN Y, ZHOU J, et al. Asiaticoside and asiatic acid improve diabetic nephropathy by restoring podocyte autophagy and improving gut microbiota dysbiosis[J]. Biochem Pharmacol, 2025, 241: 117161. doi: 10.1016/j.bcp.2025.117161 .
doi: 10.1016/j.bcp.2025.117161 |
| [49] |
LIU W, XU S, ZHANG B, et al. Ramulus Mori (Sangzhi) Alkaloids Alleviate Diabetic Nephropathy through Improving Gut Microbiota Disorder[J]. Nutrients, 2024, 16(14): 2346. doi: 10.3390/nu16142346 .
doi: 10.3390/nu16142346 |
| [50] |
XU X, GAO Z, YANG F, et al. Antidiabetic Effects of Gegen Qinlian Decoction via the Gut Microbiota Are Attributable to Its Key Ingredient Berberine[J]. Genomics Proteomics Bioinformatics, 2020, 18(6): 721-736. doi: 10.1016/j.gpb.2019.09.007 .
doi: 10.1016/j.gpb.2019.09.007 |
| [51] |
YANG X, XIN Y, GU Y, et al. Total alkaloids of Aconitum carmichaelii Debx alleviate cisplatin-induced acute renal injury by inhibiting inflammation and oxidative stress related to gut microbiota metabolism[J]. Phytomedicine, 2024, 135: 156128. doi: 10.1016/j.phymed.2024.156128 .
doi: 10.1016/j.phymed.2024.156128 |
| [52] |
XU G, YUAN H, LIU J, et al. Astragalus Mongholicus Polysaccharides Alleviate Kidney Injury in Rats with Type 2 Diabetes Through Modulation of Oxidation, Inflammation, and Gut Microbiota[J]. Int J Mol Sci, 2025, 26(4): 1470. doi: 10.3390/ijms26041470 .
doi: 10.3390/ijms26041470 |
| [53] |
DONG W, ZHAO Y, LI X, et al. Corn silk polysaccharides attenuate diabetic nephropathy through restoration of the gut microbial ecosystem and metabolic homeostasis[J]. Front Endocrinol (Lausanne), 2023, 14: 1232132. doi: 10.3389/fendo.2023. 1232132 .
doi: 10.3389/fendo.2023. 1232132 |
| [54] |
YANG J, DONG H, WANG Y, et al. Cordyceps cicadae polysaccharides ameliorated renal interstitial fibrosis in diabetic nephropathy rats by repressing inflammation and modulating gut microbiota dysbiosis[J]. Int J Biol Macromol, 2020, 163: 442-456. doi: 10.1016/j.ijbiomac.2020.06.153 .
doi: 10.1016/j.ijbiomac.2020.06.153 |
| [55] |
JIA X, LIU H, YIN G, et al. Arctium lappaL. polysaccharides alleviate oxidative stress and inflammation in the liver and kidney of aging mice by regulating intestinal homeostasis[J]. Int J Biol Macromol, 2024, 280(Pt 2): 135802. doi: 10.1016/j.ijbiomac. 2024.135802 .
doi: 10.1016/j.ijbiomac. 2024.135802 |
| [56] |
ZHANG M, YANG L, ZHU M, et al. Moutan Cortex polysaccharide ameliorates diabetic kidney disease via modulating gut microbiota dynamically in rats[J]. Int J Biol Macromol, 2022, 206: 849-860. doi: 10.1016/j.ijbiomac.2022.03.077 .
doi: 10.1016/j.ijbiomac.2022.03.077 |
| [57] |
ZHOU R, WEN W, GONG X, et al. Nephro-protective effect of Daphnetin in hyperoxaluria-induced rat renal injury via alterations of the gut microbiota[J]. J Food Biochem, 2022, 46(12): e14377. doi: 10.1111/jfbc.14377 .
doi: 10.1111/jfbc.14377 |
| [58] |
LONG C, ZHANG C, XIE Y. Study on the mechanism of hirudin multi target delaying renal function decline in chronic kidney disease based on the "gut-kidney axis" theory[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024, 397(10): 7951-7962. doi: 10.1007/s00210-023-02888-6 .
doi: 10.1007/s00210-023-02888-6 |
| [59] |
ZENG Y, DAI Z, LU F, et al. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease[J]. Oncotarget, 2016, 7(14): 17468-17478. doi: 10.18632/oncotarget.8160 .
doi: 10.18632/oncotarget.8160 |
| [60] |
LAN T, TANG T, LI Y, et al. FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis[J]. Phytomedicine, 2023, 118: 154935. doi: 10.1016/j.phymed. 2023.154935 .
doi: 10.1016/j.phymed. 2023.154935 |
| [61] |
李鑫, 洪素珍, 李宝华, 等. 升清降浊胶囊通过调节肠道菌群对db/db糖尿病肾病小鼠肾脏的保护作用及其机制探讨[J]. 中药新药与临床药理, 2022, 33(6): 742-753. doi: 10.19378/j.issn.1003-9783.2022.06.004 .
doi: 10.19378/j.issn.1003-9783.2022.06.004 |
| [62] |
ZHAO T, ZHANG H, YIN X, et al. Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats[J]. Biomed Pharmacother, 2020, 129: 110325. doi: 10.1016/j.biopha.2020.110325 .
doi: 10.1016/j.biopha.2020.110325 |
| [63] |
CHEN Q, REN D, WU J, et al. Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota[J]. J Nat Med, 2021, 75(1): 84-98. doi: 10.1007/s11418-020-01452-3 .
doi: 10.1007/s11418-020-01452-3 |
| [64] |
LIU J, GAO L, FU B, et al. Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: A multicenter, randomized controlled trial[J]. Phytomedicine, 2022, 100: 154079. doi: 10.1016/j.phymed.2022.154079 .
doi: 10.1016/j.phymed.2022.154079 |
| [65] |
杜小梅, 潘薇, 梁颖兰, 等. 参芪地黄汤加减治疗气阴两虚型糖尿病肾病疗效观察及对肠道菌群和炎症因子的影响[J]. 中药新药与临床药理, 2021, 32(4): 566-572. doi: 10.19378/j.issn.1003-9783.2021.04.018 .
doi: 10.19378/j.issn.1003-9783.2021.04.018 |
| [66] |
SHI R, TAO Y, TANG H, et al. Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice[J]. Microb Biotechnol, 2023, 16(4): 813-826. doi: 10.1111/1751-7915.14200 .
doi: 10.1111/1751-7915.14200 |
| [67] |
GAO Y, YANG R, GUO L, et al. Qing-Re-Xiao-Zheng Formula Modulates Gut Microbiota and Inhibits Inflammation in Mice With Diabetic Kidney Disease[J]. Front Med (Lausanne), 2021, 8: 719950. doi: 10.3389/fmed.2021.719950 .
doi: 10.3389/fmed.2021.719950 |
| [68] |
HONG J, FU T, LIU W, et al. Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota[J]. Diabetes Metab Syndr Obes, 2023, 16: 3707-3725. doi: 10.2147/DMSO.S441457 .
doi: 10.2147/DMSO.S441457 |
| [69] |
WEI H, WANG L, AN Z, et al. QiDiTangShen granules modulated the gut microbiome composition and improved bile acid profiles in a mouse model of diabetic nephropathy[J]. Biomed Pharmacother, 2021, 133: 111061. doi: 10.1016/J.biopha.2020. 111061 .
doi: 10.1016/J.biopha.2020. 111061 |
| [70] |
MO C, ZHAO J, LIANG J, et al. Effects of Zhuang medicine compound Xiancao Granule on diabetic kidney disease: A multi-omics analysis[J]. J Ethnopharmacol, 2024, 321: 117517. doi: 10.1016/J.JEP.2023.117517 .
doi: 10.1016/J.JEP.2023.117517 |
| [71] |
姚宇剑, 倪雅丽, 李想, 等. 缩泉益肾方对糖尿病肾病小鼠肠道菌群多样性的影响[J]. 时珍国医国药, 2020, 31(8): 1846-1848. doi: 10.3969/j.issn.1008-0805.2020.08.017 .
doi: 10.3969/j.issn.1008-0805.2020.08.017 |
| [1] | 王成,陈丹,项云霞. 基于寒热并调法探讨乌梅丸加减治疗糖尿病胃轻瘫的疗效及对IGF-1、ANO1的影响[J]. 实用医学杂志, 2026, 42(8): 1354-1360. |
| [2] | 尚萌萌,邓婕,田利民. 成人隐匿性自身免疫性糖尿病微血管并发症研究进展[J]. 实用医学杂志, 2026, 42(10): 1681-1691. |
| [3] | 熊昕,时朝阳,陈雁信,洪妙君,徐振华. 特定肠道菌群对头部创伤发病风险的因果效应:基于孟德尔随机化与荟萃分析[J]. 实用医学杂志, 2026, 42(10): 1873-1880. |
| [4] | 陆海洋,赵维莅,胡晓霞. 肠道菌群参与异基因造血干细胞移植免疫重建调控的研究进展[J]. 实用医学杂志, 2025, 41(5): 628-633. |
| [5] | 李妍,金子燃,孙皓天,刘璇,高静. 自动心肌运动定量技术评价2型糖尿病合并肾功能不全患者左心室收缩功能[J]. 实用医学杂志, 2025, 41(3): 414-421. |
| [6] | 朱丹,卢万俊,朱颖,曹金璐,陈英姿. 构建基于“无标注”眼底全景视网膜图像深度学习模型预测糖尿病肾病[J]. 实用医学杂志, 2025, 41(22): 3598-3608. |
| [7] | 罗宇沣,梁彪,陈晓东,杨小乔,何玲. 肠道菌群失调与大肠息肉和幽门螺杆菌感染肠化生的关系[J]. 实用医学杂志, 2025, 41(21): 3352-3357. |
| [8] | 高晶,赵锦,王凡,刘康. 不同频率血液透析滤过联合高通量血液透析治疗对糖尿病肾病维持性血液透析患者肾功能、微炎症状态及左心功能的影响[J]. 实用医学杂志, 2025, 41(21): 3398-3404. |
| [9] | 周欣,岳滨,柳越冬. 以“肺-肠轴”理论分析参苓白术散加减与针刺联合对溃疡性结肠炎患者的影响[J]. 实用医学杂志, 2025, 41(21): 3455-3461. |
| [10] | 杨杰,邓淑坤,袁鹏,师亚晨,马雪梅,苏旻. 基于肠道菌群理论探讨益生菌联合运动康复在帕金森病患者中的疗效[J]. 实用医学杂志, 2025, 41(20): 3191-3197. |
| [11] | 敬金洲,李泽林,罗争意,胡玉莹. 肠道菌群失调与青春期社交隔离小鼠认知障碍的关联性及关键致病菌群鉴定[J]. 实用医学杂志, 2025, 41(19): 3000-3007. |
| [12] | 黄艺霖,李爽,贺正庸,张泽宇. 肠道菌群在高血压治疗中的研究进展[J]. 实用医学杂志, 2025, 41(19): 3129-3134. |
| [13] | 田云芬,王斌,章放香. 短链脂肪酸多靶点调控脓毒症器官保护的研究进展[J]. 实用医学杂志, 2025, 41(13): 2105-2110. |
| [14] | 王佳慧,郑可,李雪梅. 脂质组学在肾脏疾病中的应用与进展[J]. 实用医学杂志, 2025, 41(1): 1-6. |
| [15] | 张锐,周颖,倪文吉,黄亚,李丹丹,金涛,钟勇. 人工智能视网膜微血管分析在糖尿病并发症中的应用价值[J]. 实用医学杂志, 2024, 40(8): 1142-1147. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||


